このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Sight Sciences マネジメント

マネジメント基準チェック /34

Sight Sciences'の CEO はPaul Badawiで、 Jan2011年に任命され、の在任期間は 13.42年です。の年間総報酬は$ 3.90Mで、 15.6%給与と84.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の10.36%を直接所有しており、その価値は$ 33.25M 。経営陣と取締役会の平均在任期間はそれぞれ4.2年と4.3年です。

主要情報

Paul Badawi

最高経営責任者

US$3.9m

報酬総額

CEO給与比率	15.6%
CEO在任期間	13.5yrs
CEOの所有権	10.4%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	4.4yrs

経営陣の近況

Recent updates

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 19

Analysts Have Been Trimming Their Sight Sciences, Inc. (NASDAQ:SGHT) Price Target After Its Latest Report

Mar 26

Sight Sciences: Appeal Is Visually Increasing

Jan 13

CEO報酬分析

Sight Sciences の収益と比較して、Paul Badawi の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$55m
Dec 31 2023	US$4m	US$610k	-US$56m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$71m
Mar 31 2023	n/a	n/a	-US$80m
Dec 31 2022	US$6m	US$580k	-US$86m
Sep 30 2022	n/a	n/a	-US$85m
Jun 30 2022	n/a	n/a	-US$80m
Mar 31 2022	n/a	n/a	-US$74m
Dec 31 2021	US$9m	US$424k	-US$63m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$497k	US$360k	-US$35m

報酬と市場: Paulの総報酬 ($USD 3.90M ) は、 US市場 ($USD 2.45M ) の同規模の企業の平均を上回っています。

報酬と収益: Paulの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Paul Badawi (49 yo)

13.5yrs

在職期間

US$3,902,022

報酬

Mr. Paul Badawi is a Co-Founder of Sight Sciences, Inc. since 2011 and serves as its President and Chief Executive Officer since 2011. Mr. Badawi specializes in medical technology investments for 3i. His p...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paul Badawi	Co-Founder	13.5yrs	US$3.90m	10.36% $ 31.9m
David Badawi	Founder	13.5yrs	データなし	3.22% $ 9.9m
Alison Bauerlein	CFO & Treasurer	1.3yrs	US$1.85m	0.081% $ 249.0k
Matthew Link	Chief Commercial Officer	less than a year	US$2.36m	データなし
Sam Park	Chief Operating Officer	4.3yrs	US$1.86m	0.12% $ 354.4k
Jeremy Hayden	Chief Legal Officer	4.3yrs	データなし	0.034% $ 103.7k
Steve Tamayo	VP and Chief Ethics & Compliance Officer	1.2yrs	データなし	データなし
Reay Brown	Chief Medical Officer	5.8yrs	データなし	データなし
Stephen Thau	Secretary	no data	データなし	データなし
Jim Rodberg	VP of Finance & Corporate Controller	no data	データなし	0.0014% $ 4.3k

4.3yrs

平均在職期間

51.5yo

平均年齢

経験豊富な経営陣: SGHTの経営陣は経験豊富であると考えられます ( 4.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul Badawi	Co-Founder	13.5yrs	US$3.90m	10.36% $ 31.9m
David Badawi	Founder	13.5yrs	データなし	3.22% $ 9.9m
Erica Rogers	Independent Director	4.7yrs	US$182.30k	0.22% $ 684.0k
Donald Zurbay	Independent Director	4.1yrs	US$187.50k	0.20% $ 619.6k
Brenda Becker	Independent Director	2.3yrs	US$167.33k	0.0074% $ 22.8k
Staffan Encrantz	Independent Chairman	6.8yrs	US$207.91k	4.41% $ 13.6m
Tamara Fountain	Independent Director	2yrs	US$401.06k	0.042% $ 130.5k
Catherine Mazzacco	Independent Director	1.1yrs	US$256.34k	0.037% $ 112.7k

4.4yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: SGHTの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

Sight Sciences マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Co-Founder recently sold US$81k worth of stock

CFO & Treasurer recently sold US$71k worth of stock

Sight Sciences, Inc., Annual General Meeting, Jun 06, 2024

Co-Founder recently sold US$64k worth of stock

Co-Founder recently sold US$82k worth of stock

Co-Founder notifies of intention to sell stock

Recent updates

Co-Founder recently sold US$81k worth of stock

Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma

CFO & Treasurer recently sold US$71k worth of stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024

Sight Sciences, Inc., Annual General Meeting, Jun 06, 2024

Sight Sciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Sight Sciences, Inc. Announces the Publication of Large-Scale, Real-World Migs Study

Co-Founder recently sold US$64k worth of stock

Sight Sciences, Inc. Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT At the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Provides Earnings Guidance for the Year 2024

New minor risk - Insider selling

Sight Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Sight Sciences, Inc. Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting

Sight Sciences, Inc. announced that it expects to receive $65 million in funding

Co-Founder recently sold US$82k worth of stock

Co-Founder notifies of intention to sell stock

Sight Sciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Sight Sciences, Inc. Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Sight Sciences Announces the Acceptance for Publication of Gemini 2, A Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant Iop and Medication Reductions Enabled with the Omni® Surgical System Technology

Independent Chairman recently bought US$278k worth of stock

Some Analysts Just Cut Their Sight Sciences, Inc. (NASDAQ:SGHT) Estimates

Price target decreased by 49% to US$3.13

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

New minor risk - Market cap size

Sight Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sight Sciences, Inc. Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Chief Operating Officer exercised options to buy US$130k worth of stock.

Sight Sciences, Inc. Revises Revenue Guidance for the Full Year 2023

Price target decreased by 8.1% to US$10.48

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sight Sciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Sight Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 12% to US$12.80

Sight Sciences Announces Appointment of Catherine Mazzacco as New Director

Sight Sciences Two Year Multicenter Study Results Shows Sustained Reductions in Both Intraocular Pressure and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with A Procedure Enabled with the Omni Surgical System Technology

Sight Sciences, Inc. Announces 12-Month Results from the First Minimally Invasive Glaucoma Surgery

First quarter 2023 earnings: EPS exceeds analyst expectations

Sight Sciences Reaffirms Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Announces Executive Changes

Price target increased to US$14.60

Sight Sciences, Inc. Reports Improvements in Signs and Symptoms of Dry Eye Disease from A Single Tearcare

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Sight Sciences, Inc. Provides Revenue Guidance for Full Year 2022

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients

Sight Sciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Sight Sciences, Inc. Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare(R) System Compared to Lipiflow in Patients with Advanced Dry Eye Disease (DED)

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare(R) System vs Restasis

Sight Sciences Introduces the Sion(Tm) Surgical Instrument -- the First Bladeless Device Used in Goniotomy

Sight Sciences Grows Portfolio Amid Reimbursement Pressure

Sight Sciences, Inc. Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI(R) Surgical System in Patients with Open Angle Glaucoma

Sight Sciences, Inc. Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sight Sciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$14.50

Sight Sciences, Inc. Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

Sizing Up Sight Sciences

Sight Sciences, Inc. Announces Publication in Clinical Ophthalmology of Its 12-Month Outcomes in the Gemini Study, Including Results from A Hispanic Population Subset

Independent Chairman recently bought US$4.6m worth of stock

Sight Sciences, Inc. Affirmes Revenue Guidance for the Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

マネジメント基準チェック /34